Phase Ib open-label rising-dose study of biomed 101 in patients treated with interleukin-2 for malignancy.
Phase of Trial: Phase I
Latest Information Update: 20 May 2009
At a glance
- Drugs Biomed 101 (Primary) ; Interleukin-2
- Indications Renal cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 13 Feb 2008 The expected completion date for this trial is now 1 Dec 2002.
- 28 Jan 2008 Status changed from in progress to completed.